{
  "docId": "019de072-4935-7342-8528-4e6eca3fe5c7",
  "docSlug": "31ea92baba83669e6443d115d329d67b",
  "documentTitle": "AstraZeneca | Investor Presentation Deck | 53 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 53,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes ASCO GI 2022 callout and regulatory submission status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4935-7342-8528-4e6eca3fe5c7/46",
  "deckHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7",
  "deckJsonHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7.json",
  "deckAnchorHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.68,
        "y": 0.83
      },
      "kind": "callout",
      "text": "IO-only combination strategy simplifies patient management",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "446b50b9-61a4-4551-9ece-620a533d15d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.1,
        "x": 0.85,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Regulatory submissions in H1 2022",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80d18c24-cfa8-42f1-a983-f4885a1e0272",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.07,
        "x": 0.91,
        "y": 0.16
      },
      "kind": "callout",
      "text": "ASCO GI 2022",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea4c0f91-f587-42c6-9ad5-98d1065dc15f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "list",
      "text": "First IO+IO combination in first-line advanced, unresectable HCC. Only Phase III trial to show benefit of single, priming dose of CTLA-4. Impressive three-year landmark OS data with almost 1 in 3 patients alive at three years on STRIDE regimen versus one in five on sorafenib",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "305042b8-42b9-4f74-9c74-a24b452c04c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.3,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "Innovative STRIDE regimen with tremelimumab",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90654361-a15b-4a8a-88a4-51cd4e93bb18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "list",
      "text": "Imfinzi monotherapy non-inferior to sorafenib, with numerical advantage in OS. No increased bleeding risk or severe liver toxicity seen in trials. Exceptional safety profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f6a5cec-03a9-4756-b1d9-292d7382119f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.28,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Large unmet need in liver cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa941167-817f-4a4e-b880-bc3ec709b8ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.28,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "list",
      "text": "Clear efficacy, safety and simplicity for patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3a5f16f-20be-4524-af1f-8c55a9aa2e76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.04,
        "y": 0.49
      },
      "kind": "metric",
      "text": "7% five-year survival in advanced HCC",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23c4a8e8-9f2e-4165-9821-f8a6429f3cf1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.04,
        "y": 0.36
      },
      "kind": "metric",
      "text": "3rd leading cause of cancer death worldwide",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd205652-ff03-4cf8-a691-0311cbdf53a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.28,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "metric",
      "text": "At least 40% of treatment eligible first-line advanced HCC patients are at risk of bleeding",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d11174f4-d500-447d-af58-1ae52cb15581",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.28,
        "x": 0.04,
        "y": 0.83
      },
      "kind": "paragraph",
      "text": "~80,000 people in the US, Europe and Japan and 260,000 people in China present with advanced, unresectable HCC each year",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "727b4c6a-a7bf-444b-8d35-6f993943729e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "46 1. ASCO. Liver Cancer: Accessed January 2022. 2. Sayiner M, et al. Digestive Diseases and Sciences. 2019; 64: 910-917. 3. Boregowda et al. World J Gastrointest Pharmacol Ther. 2019 Jan 21; 10(1): 1-21. 4. AstraZeneca data on file.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49a6ad2f-e1b2-4ca8-8af8-f2843b6dc61b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "HIMALAYA – an innovative IO regimen delivering survival benefit to patients with advanced, unresectable hepatocellular carcinoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4faae93d-6751-4ca2-8fb6-fe43ad0e1c8b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}